Identifying Monoclonal Antibody Mutation Sites Using the Agilent 1290 Infinity II 2D-LC Solution with Q-TOF LC/MS Application Note Biopharmaceuticals and Biosimilars Authors Abstract Koen Sandra, Gerd Vanhoenacker, In recent years, 2D-LC has been highly promising for the detailed characterization Mieke…
Klíčová slova
infliximab, biosimilar, originator, rplc, slslspgk, slslspg, ydywgqgttltvssastk, candidate, nyygstydywgqgttltvssastk, biosimilars, peptide, dimension, dimensional, mutations, heavy